Heidelberg-based Graffinity Pharmaceuticals AG is the latest German biotech to use M&A to morph from a platform into a product company. Until a few weeks ago, Graffinity was a typical German biotech. Founded in 1998 at the height of the country's government-funded BioRegio program, the company was built on the back of a series of clever technologies designed to help others discover and develop drugs.
Since then, the platform technology model has fallen out of favor. Shifting priorities at Big Pharma customers, the commoditization of technology and the painful market correction have led to an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?